Time to shut down NIBR
- Thread starter Anonymous
- Start date
-
- Tags
- None
bred - "a contraction for the word 'bread' which is another word for 'money'"
inbred -"a contraction of the phrase 'in the bread' so its meaning is 'having lots of money'"
If not, a description of your genetic origins.
Very bad middle and top management -only interested in the own carrier and job
Will Novartis "double down" on the, so far, loosing strategy that NIBR is based on or will they follow AZ's lead?
"Drug giant AstraZeneca AZN.LN -0.65% PLC, seeking to invigorate a depleting drug pipeline, Monday set out plans for a reorganization of its global research and development operations, which will include eliminating around 1,600 jobs over three years and relocating its headquarters to Cambridge, England."
http://online.wsj.com/article/SB10001424127887323415304578368293298645344.html?mod=googlenews_wsj
"Drug giant AstraZeneca AZN.LN -0.65% PLC, seeking to invigorate a depleting drug pipeline, Monday set out plans for a reorganization of its global research and development operations, which will include eliminating around 1,600 jobs over three years and relocating its headquarters to Cambridge, England."
http://online.wsj.com/article/SB10001424127887323415304578368293298645344.html?mod=googlenews_wsj
Start with closing NIBR Basel by 'deinvesting' the management there
Frankly, I met incredibly talented scientists at NIBR, with insight and farsightedness. Many of the scientists are a million times better than the guys I have seen at e.g. Lilly and Abbott. For example Jeff Porter, Tewis Bouwemester, Chris Wilson, and in general most of the DMP people are absolutely outstanding. There are some idiots as well (whom I shall not name) but they are neutralized by the gret ones. Give them more time - research is tough and discoveries cannot be planned. My prediction is that great drugs will come about over time. And maybe a Nobel Prize as well.
I do have some concerns about NIBR though. The structures are too vertical, and the decisional power is too concentrated on the top. A bit more "subsidiarity" and empowerment of the middle layer might go a long way towards making happier coworkers and enhanced productivity. But these are quibbles - in general we are talking about a great powerhouse of science.
I do have some concerns about NIBR though. The structures are too vertical, and the decisional power is too concentrated on the top. A bit more "subsidiarity" and empowerment of the middle layer might go a long way towards making happier coworkers and enhanced productivity. But these are quibbles - in general we are talking about a great powerhouse of science.
------------------------
I am looking for some info from someone who knows the NIBR system. What is the difference between lab head and group leader. And do lab heads work on bench ? Also what is typical starting salary for a lab head ?
is it better to be a cook or a sailor on the most admired ship of the world? What is the difference between a cook and a sailor? Do cooks work in a kitchen? How much do you make as a cook on the MS Titanic?
RUN!!!!!!!!!!!!!!!!!!!!!!
or it could be the old "bath tub curve" from a very naive scientists raising its head again.
Rumor says NIBR is shutting down research @ Alcon (Ft Worth)& moving all to Cambrige. Anyone have info?
Yes, Fort Worth research is gone as of 4/19 unless they are lucky enough to find jobs in FTW or Cambridge. Sad day for the dedicated workers in Texas.
Will this benifit NIBR? Who knows. Have to think though that loss of all of the experience and knowledge in opthalmology has to be a huge negative.
Will this benifit NIBR? Who knows. Have to think though that loss of all of the experience and knowledge in opthalmology has to be a huge negative.
Is NIBR an academic institute or part of a pharma company? Someone please tell me
Pure Pharma staffed by academicians who are allowed to publish now and again if it will not reveal too many trade secrets.
NIBR, as a concept has been, so far at least, a total flop.
NIBR appears to be a cadre of inexperienced academics. Unfortunately, they and their leaders lack sufficient corporate pharma experience. They may have laudable scientific knowledge but the odds of translating that knowledge to viable/commercially-successful drug candidates are quite low. I don't fault the researchers themselves, but do fault those at management level (because they are equally inexperienced).
Please cite an example of "corporate pharma" that is working.
As usual, NIBR is screwing up big time closing down Alcon R&D.
As a point of reference, I was a NIBR scientist and left with most of my soul intact. Absolutely correct that a lot of deep thinkers there with little foresight of the low hanging fruit that could make it to market. All they see the shiny apple at the top of the tree.
Sad to see NIBR gut Alcon's optha assets. Personally, I would rather live in Texas than Cambridge any day.
As a point of reference, I was a NIBR scientist and left with most of my soul intact. Absolutely correct that a lot of deep thinkers there with little foresight of the low hanging fruit that could make it to market. All they see the shiny apple at the top of the tree.
Sad to see NIBR gut Alcon's optha assets. Personally, I would rather live in Texas than Cambridge any day.
It is indeed sad to see a strong R&D hub at alcon close, but the writing was on the wall. with none of fishmans roommates or academic butt buddies from medical school at alcon, they never really had a chance. same old crap, new victim. you have to be a yes man, lap dog insider to get ahead within NIBR (not somethng texans take to kindly), a culture that will come back to bite all of management in the ass, as the NIBR research scuffle cannot be bankrolled indefinitely.
I ask this question again. Please answer it or shut up about NIBR.